The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension

American Journal of Hypertension

Volumn 17, Issue 3, 2004, Pages 273-276

  Zervoudaki, Alexandra ^a,b   Economou, Emanuel ^a   Pitsavos, Christos ^a   Vasiliadou, Karmen ^a   Aggeli, Constantina ^a   Tsioufis, Konstantinos ^a   Toutouza, Marina ^a   Stefanadis, Christodoulos ^a   Toutouzas, Pavlos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

Extracellular matrix; Metalloproteinases; Remodeling

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FELODIPINE; GELATINASE A; GELATINASE B; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIASTOLE; ENZYMOLOGY; HEART VENTRICLE; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ADULT; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIASTOLE; DILTIAZEM; FELODIPINE; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; SYSTOLE; TREATMENT OUTCOME; VASCULAR RESISTANCE;

EID: 1442274816     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2003.11.007     Document Type: Article

References (15)

1. Intengan H.D., Schiffrin E.L. Structure and mechanical properties of resistance arteries in hypertension. Role of adhesion molecules and extracellular matrix determinants. Hypertension. 36:2000;312-318.
2. Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension. Roles of apoptosis, inflammation, and fibrosis. Hypertension. 38:2001;581-587.
3. Ruilope L.M., Schiffrin E.L. Blood pressure control and benefits of antihypertensive therapy. Does it make a difference which agents we use? Hypertension. 38:2001;537-542.
4. Zervoudaki A., Economou E., Stefanadis C., Pitsavos C., Tsioufis K., Aggeli C., Vasiliadou K., Toutouza M., Toutouzas P. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens. 17:2003;119-124.
5. Laviades C., Varo N., Fernandez J., Mayor G., Gil M., Monreal I., Diez J. Abnormalites of the extracellular degradation of collagen type I in essential hypertension. Circulation. 98:1998;535-540.
6. Brilla C.G., Moderer S., Salge U., Heidmann H.H. Collagenolytic activity in left ventricular endomyocardial biopsies of patients with hypertensive heart disease or hypertrophic cardiomyopathy. (Abstract) Circulation. 90:(Suppl I):1994;I-264.
7. Li-Saw-Hee F.L., Edmunds E., Blann A.D., Beevers D.G., Lip G. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Card. 75:2000;43-47.
8. Laurent S., Kingwell B., Bank A., Weber M., Boudier-Struijker H. Clinical applications of arterial stiffness therapeutics and pharmacology. Am J Hypertens. 15:2002;453-458.
9. Hirono O., Fatema K., Nitobe J., Takeishi Y., Kaneko K., Shiga R., Kubota I. Long-term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol. 39:2002;195-204.
10. Ikeda U., Hojo Y., Ueno S., Arakawa H., Shimada K. Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells. J Cardiovasc Pharmacol. 35:2000;887-890.
11. Oparil S., Weber M.A. Hypertension: a companion to Brenner and Rector's The Kidney. 2000;609-620 WB Saunders, Philadelphia.
12. 2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA. 93:1996;5478-5482.
13. Waba Y., Kato S., Okamoto K., Izzumaru S., Aoyagi S., Morimatsu M. Diltiazem, a calcium antagonist, inhibits matrix metalloproteinases-1 (tissue collagenase) production and collagenolytic activity in human vascular smooth muscle cells. Int J Mol Med. 8:2001;561-566.
14. Bellosta S., Canavesi M., Favari E., Cominacini L., Gaviraghi G., Fumagalli R., Paoletti R., Bernini F. Lacidipine (correction of lalsoacidipine) modulates the secretion of matrix metalloproteinases-9 by human macrophages. J Pharmacol Exp Ther. 2:2001;736-743.
15. Boyle J.R., Loftus I.M., Goodall S., Crowther M., Bell P.R., Thompson M.M. Amlodipine potentiates metalloproteinases activity and accelerates elastin degradation in a model of aneurismal disease. Eur J Vasc Endovasc Surg. 16:1998;408-414.